Prothena
1 known investors
Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.
Biotech
Investors · 1
In the news
- Tickerontickeron.com · 2026
- Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Biotech Headwinds Amid Pipeline Delaysad-hoc-news.de · 2026
- Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situationfinance.yahoo.com · 2024
- Prothena - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2023
- Prime Medicine Launches with $315 Million to Deliver on the Promise of Prime Editing - Global Genesglobalgenes.org · 2021
- Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market - TheStreetthestreet.com · 2017